Trial · NCT05497804
Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial
NCT05497804, Phase 2, Active not recruiting, Mayo Clinic
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial. Trials, record NCT05497804. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05497804
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial
- NCT number
- NCT05497804
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 17 participants, actual
- Lead sponsor
- Mayo Clinic
- Conditions
- ISS Stage III Plasma Cell Myeloma, Multiple Myeloma
- Interventions
Bone Marrow Aspiration and Biopsy, Carfilzomib, Computed Tomography, Daratumumab, Dexamethasone, Lenalidomide, Magnetic Resonance Imaging, Positron Emission Tomography, Multigated Acquisition Scan, Biospecimen Collection, Echocardiography, Chest Radiography
- First posted
- 2022-08-11
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Rate of Sustained Minimal Residual Disease (MRD) Negativity | 1 year | MRD negative status at any point, with a repeated MRD negative status one year later. All subjects meeting the eligibility criteria who have signed a consent form and have begun treatment will be evaluable, with the exception of subjects determined to be a major violation. The International Myeloma Working Group (IMWG) uniform response criteria (Kumar et al, \>\>\> 2016) was used for response assessment. |
| Secondary | Overall Response Rate | At the end of induction (up to 1 year after start of induction treatment) and at the end of consolidation (up to 3 years after start of induction treatment) | The overall response rate will be defined as the percentage of patients that achieved confirmed very good partial response (VGPR) or better by The International Myeloma Working Group (IMWG) uniform response criteria (Kumar et al, 2016) at the designated timepoint. |
| Secondary | Overall Survival | 3 years | Defined as the time from registration to death due to any cause. The distribution of overall survival will be estimated using the method of Kaplan-Meier. |
| Secondary | Progression-Free Survival | 3 years | Defined as the time from registration to the earliest date of documentation of disease progression or death due to any cause. The distribution of progression-free survival will be estimated using the method of Kaplan-Meier. |
| Secondary | Incidence of Adverse Events | Monthly up to 3 years after start of induction treatment | Adverse Events: All eligible subjects that have initiated treatment will be considered evaluable for assessing adverse event rate(s). The maximum grade for each type of adverse event will be recorded for each subject, and frequency tables will be reviewed to determine patterns. Additionally, the relationship of the adverse event(s) to the trial treatment will be taken into consideration. AEs will be summarized overall, as well as by treatment phase (induction, consolidation, maintenance with carfilzomib and lenalidomide and daratumumab). The percent of patients with a grade 3 or higher event will be reported for both the Induction and Consolidation timepoints. |
| Other | Clonal Architecture Before Treatment | Before and after treatment, up to two years or 24 months | To determine the clonal architecture before treatment, after treatment in subjects with residual disease and in subjects who have disease progression after attaining MRD negativity. |
| Other | Bone Marrow Microenvironment | Before and after treatment, up to two years or 24 months | To evaluate the bone marrow microenvironment before and after treatment and the time of MRD negative state. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants2
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|---|---|---|---|---|---|
| P50CA186781 | Mayo Clinic Multiple Myeloma SPORE - Renewal 2025 | Bergsagel, Peter Leif | MAYO CLINIC ARIZONA | NATIONAL CANCER INSTITUTE | 2015 to 2026 | NIH RePORTER |
| P30CA015083 | Mayo Clinic Comprehensive Cancer Center Support Grant | WILLMAN, CHERYL LYNN | MAYO CLINIC ROCHESTER | NATIONAL CANCER INSTITUTE | 1985 to 2025 | NIH RePORTER |
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05497804
GET https://conductscience.org/api/trials/v1/NCT05497804/registered